IL1A and coronary artery disorder: Reduces serum levels and expression of TNF-α and IL-1 in patients with type II diabetes mellitus and coronary artery disease. Inversely correlated with plasma IL-6. Improves wall shear stress, left ventricular function, and blood pressure in pre-clinical studies.